Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Shubham Pant, MD, MBBS; Alison Schram, MD; and Helena Yu, MD, discuss the role of RAS alterations in solid tumors, including gastrointestinal, gynecologic, and thoracic malignancies.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Assess the role of KRAS/RAS mutations across solid tumors and biomarker testing implications
• Differentiate efficacy and safety profiles of current and emerging KRAS/RAS-targeted therapies in solid tumors
• Apply clinical trial data on KRAS/RAS-targeted therapies to individualized treatment selection for patients with solid tumors
• Develop appropriate adverse-event mitigation and management approaches for patients with solid tumors receiving KRAS/RAS-targeted therapies

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Revolution Medicines.

Chair:

Shubham Pant, MD, MBBS

Professor
Department of Investigational Cancer Therapeutics
Department of Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Advisor/Consultant/Speaker/Honoraria Recipient: Alligator Bioscience, Arcus, AskGene Pharma, AstraZeneca, Boehringer Ingelheim, BPGbio, Bristol Myers Squibb, Janssen, Jazz Pharmaceuticals, Merck, Nihon Medi-Physics Co Ltd, Novartis, Pfizer, Revolution Medicines, Theriva Biosciences, US WorldMeds, Zymeworks; Grant/Research Funding: Amal Therapeutics, Arcus, Astellas, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Elicio, FrameWave, Immuneering, ImmunoMet Therapeutics, Ipsen, Janssen, Jazz Pharmaceuticals, Lilly, Mirati Therapeutics, NGM Pharmaceuticals, Novartis, Pfizer, Revolution Medicines, Zymeworks; Ownership interests in privately held companies: Telperian

Faculty:

Alison Schram, MD

Associate Attending Physician
Early Drug Development and Gynecologic Medical Oncology Services
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Boehringer Ingelheim, Guardant Health, Merus, Partner Therapeutics, Revolution Medicines; Grant/Research Funding:AstraZeneca, BeiGene, Boehringer Ingelheim, Kura Oncology, Lilly, Merus, Partner Therapeutics, Pfizer, Relay Therapeutics, Revolution Medicines.

Helena Yu, MD

Attending
Research Director, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Amgen, AstraZeneca, Black Diamond Therapeutics, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Pfizer, Taiho; Grant/Research Funding (to institution): AstraZeneca, Cullinan Therapeutics, Daiichi, Janssen, Kumquat Biosciences, Pfizer, SystImmune, Taiho

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on the mechanism of action of RAS inhibitors and the epidemiology of RAS alterations in gynecologic malignancies, go to https://www.gotoper.com/cfs25kras-enduring.

Release Date

January 22, 2026

Expiration Date

January 22, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.